UNSPSC 51401504: Cinolazepam

This classification denotes a benzodiazepine with the molecular formula C18H13ClFN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 68P0556B0U, chemically known as 7-chloro-5-(o-fluorophenyl)-2,3-dihydro-3-hydroxy-2-oxo-1h-1,4-benzodiazepine-1-propionitrile but generally known as cinolazepam, which bears US NIH Compound Identifier 3033621. European Medicines Agency schedules Cinolazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06307MIG.

UNSPSC 51401504 Cinolazepam is a Commodity code that nominally refers to a specific benzodiazepine medication, but recent state and local procurement activity under this code diverges significantly from that narrow pharmaceutical classification. The actual solicitations posted show state and local governments purchasing broader pharmaceutical supply agreements, naloxone (an opioid antagonist), and over-the-counter products through cooperative purchasing vehicles and direct manufacturer arrangements. State and local issuing bodies under this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The work involves establishing supply contracts with manufacturers and wholesalers to furnish pharmaceutical products—generics, OTC items, and emergency medications like naloxone—to public health facilities and employee health plans across multiple jurisdictions.

Recent activity is concentrated in three states. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, due July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, designed to inform future formal procurement strategy. The Minnesota Department of Administration, through MMCAP, posted RFP S1070000015802 on January 20, 2026, due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, with awarded vendors to be effective July 1, 2026, and requiring compliance with cGMP, DSCSA, FDA requirements, and a 3 percent administrative fee structure.